FDA approves first generics to compete with duloxetine - Eli Lilly
The FDA has announced that it has approved the first generic versions of Cymbalta (duloxetine delayed-release capsules) from Eli Lilly, a prescription medicine used to treat depression and other conditions. Aurobindo Pharma, Dr Reddy�s Laboratories, Lupin, Sun Pharma Global, Teva Pharmaceuticals USA and Torrent Pharmaceuticals have all received FDA approval to market duloxetine in various strengths.
The US patent on Cymbalta expired on 11 December 2013. In Europe and Australia, the patent on Cymbalta already expired in December 2012. However, data exclusivity in Europe lasts until August 2014 and in Canada data and market exclusivity periods last until May 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins